Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis

Journal of Immunology

Volumn 183, Issue 3, 2009, Pages 1813-1820

  Selvapandiyan, Angamuthu ^a   Dey, Ranadhir ^a   Nylen, Susanne ^b   Duncan, Robert ^a   Sacks, David ^b   Nakhasi, Hira L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRIN; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; NITRIC OXIDE; TUMOR NECROSIS FACTOR; LEISHMANIA VACCINE; LIVE VACCINE;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; GENE DELETION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LIVER; MACROPHAGE; MALE; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; SPLEEN; TH1 CELL; VISCERAL LEISHMANIASIS; ANIMAL; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; PARASITOLOGY; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CRICETINAE; HUMANS; IMMUNITY; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; TH1 CELLS; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 68149182303     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900276     Document Type: Article

References (42)

1. Selvapandiyan, A., R. Duncan, A. Debrabant, N. Lee, G. Sreenivas, P. Salotra, and H. L. Nakhasi. 2006. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J. Med. Res. 123: 455-466.
2. Silvestre, R., A. Cordeiro-da-Silva, and A. Ouaissi. 2008. Live attenuated Leishmania vaccines: a potential strategic alternative. Arch. Immunol. Ther. Exp. 56: 123-126.
3. Streit, J. A., T. J. Recker, F. G. Filho, S. M. Beverley, and M. E. Wilson. 2001. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J. Immunol. 166: 1921-1929.
4. Titus, R. G., F. J. Gueiros-Filho, L. A. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92: 10267-10271.
5. Amaral, V. F., A. Teva, M. P. Oliveira-Neto, A. J. Silva, M. S. Pereira, E. Cupolillo, R. Porrozzi, S. G. Coutinho, C. Pirmez, S. M. Beverley, and G. Grimaldi, Jr. 2002. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz 97: 1041-1048.
6. Spath, G. F., L. F. Lye, H. Segawa, D. L. Sacks, S. J. Turco, and S. M. Beverley. 2003. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 301: 1241-1243.
7. Uzonna, J. E., G. F. Spath, S. M. Beverley, and P. Scott. 2004. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol. 172: 3793-3797.
8. Spath, G. F., L. F. Lye, H. Segawa, S. J. Turco, and S. M. Beverley. 2004. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect. Immun. 72: 3622-3627.
9. hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur. J. Immunol. 38: 3090-3100.
10. Alexander, J., G. H. Coombs, and J. C. Mottram. 1998. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161: 6794-6801. (Pubitemid 28562223)
11. Saravia, N. G., B. Escorcia, Y. Osorio, L. Valderrama, D. Brooks, L. Arteaga, G. Coombs, J. Mottram, and B. L. Travi. 2006. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 24: 4247-4259.
12. Papadopoulou, B., G. Roy, M. Breton, C. Kundig, C. Dumas, I. Fillion, A. K. Singh, M. Olivier, and M. Ouellette. 2002. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 70: 62-68.
13. Zhang, W. W., and G. Matlashewski. 2001. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol. Microbiol. 39: 935-948.
14. Silvestre, R., A. Cordeiro-Da-Silva, N. Santarem, B. Vergnes, D. Sereno, and A. Ouaissi. 2007. SIR2-deficient Leishmania infantum induces a defined IFN-γ/ IL-10 pattern that correlates with protection. J. Immunol. 179: 3161-3170.
15. Selvapandiyan, A., A. Debrabant, R. Duncan, J. Muller, P. Salotra, G. Sreenivas, J. L. Salisbury, and H. L. Nakhasi. 2004. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J. Biol. Chem. 279: 25703-25710.
16. Selvapandiyan, A., R. Duncan, A. Debrabant, S. Bertholet, G. Sreenivas, N. S. Negi, P. Salotra, and H. L. Nakhasi. 2001. Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite. J. Biol. Chem. 276: 43253-43261.
17. Selvapandiyan, A., P. Kumar, J. C. Morris, J. L. Salisbury, C. C. Wang, and H. L. Nakhasi. 2007. Centrin1 is required for organelle segregation and cytokinesis in Trypanosoma brucei. Mol. Biol. Cell 18: 3290-3301.
18. Mahajan, B., A. Selvapandiyan, N. J. Gerald, V. Majam, H. Zheng, T. Wickramarachchi, J. Tiwari, H. Fujioka, J. K. Moch, N. Kumar, et al. 2008. Centrins, cell cycle regulation proteins in human malaria parasite Plasmodium falciparum. J. Biol. Chem. 283: 31871-31883.
19. Salisbury, J. L. 1995. Centrin, centrosomes, and mitotic spindle poles. Curr. Opin. Cell Biol. 7: 39-45.
20. Spath, G. F., and S. M. Beverley. 2001. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99: 97-103.
21. + regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
22. Selvapandiyan, A., R. Duncan, J. Mendez, R. Kumar, P. Salotra, L. J. Cardo, and H. L. Nakhasi. 2008. A Leishmania minicircle DNA footprint assay for sensitive detection and rapid speciation of clinical isolates. Transfusion 48: 1787-1798.
23. Buxbaum, L. U., H. Denise, G. H. Coombs, J. Alexander, J. C. Mottram, and P. Scott. 2003. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J. Immunol. 171: 3711-3717.
24. Dey, R., A. Sarkar, N. Majumder, S. Bhattacharyya Majumdar, K. Roychoudhury, S. Bhattacharyya, S. Roy, and S. Majumdar. 2005. Regulation of impaired protein kinase C signaling by chemokines in murine macrophages during visceral leishmaniasis. Infect. Immun. 73: 8334-8344.
25. Scott, P. 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147: 3149-3155.
26. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
27. Nylen, S., and D. Sacks. 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 28: 378-384.
28. 3- Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204: 285-297.
29. Melby, P. C., B. Chandrasekar, W. Zhao, and J. E. Coe. 2001. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166: 1912-1920.
30. + T cells. Infect. Immun. 75: 4648-4654.
31. Nathan, C. 1997. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest. 100: 2417-2423. (Pubitemid 27514879)
32. Perez, L. E., B. Chandrasekar, O. A. Saldarriaga, W. Zhao, L. T. Arteaga, B. L. Travi, and P. C. Melby. 2006. Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J. Immunol. 176: 5519-5528.
33. Uzonna, J. E., G. Wei, D. Yurkowski, and P. Bretscher. 2001. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167: 6967-6974.
34. Zaph, C., J. Uzonna, S. M. Beverley, and P. Scott. 2004. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10: 1104-1110.
35. Jelley-Gibbs, D. M., D. M. Brown, J. P. Dibble, L. Haynes, S. M. Eaton, and S. L. Swain. 2005. Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J. Exp. Med. 202: 697-706.
36. Turner, D. L., L. S. Cauley, K. M. Khanna, and L. Lefrancois. 2007. Persistent antigen presentation after acute vesicular stomatitis virus infection. J. Virol. 81: 2039-2046.
37. Neal, R. A., A. Reeves, and W. Peters. 1990. Leishmania infecting man and wild animals in Saudi Arabia, 7: partial protection of mice against Leishmania major by prior infection with L. arabica. Trans. R. Soc. Trop. Med. Hyg. 84: 233-238.
38. Gicheru, M. M., J. O. Olobo, and C. O. Anjili. 1997. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp. Parasitol. 85: 109-116.
39. Lima, H. C., G. K. DeKrey, and R. G. Titus. 1999. Resolution of an infection with Leishmania braziliensis confers complete protection to a subsequent challenge with Leishmania major in BALB/c mice. Mem. Inst. Oswaldo Cruz. 94: 71-76.
40. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150: 2322-2331. (Pubitemid 23127477)
41. Tonui, W. K., and R. G. Titus. 2007. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c mice. Am. J. Trop. Med. Hyg. 76: 579-584.
42. Bhowmick, S., T. Mazumdar, and N. Ali. 2009. Vaccination route that induces transforming growth factor β production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun. 77: 1514-1523.